Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to -$15.3 million.

  • OptimizeRx's Income from Continuing Operations rose 10853.79% to $779000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 11520.25%. This contributed to the annual value of -$15.3 million for FY2024, which is 1282.02% up from last year.
  • Per OptimizeRx's latest filing, its Income from Continuing Operations stood at -$15.3 million for FY2024, which was up 1282.02% from -$17.6 million recorded in FY2023.
  • OptimizeRx's 5-year Income from Continuing Operations high stood at $378079.0 for FY2021, and its period low was -$17.6 million during FY2023.
  • For the 5-year period, OptimizeRx's Income from Continuing Operations averaged around -$9.2 million, with its median value being -$11.4 million (2022).
  • In the last 5 years, OptimizeRx's Income from Continuing Operations soared by 11712.99% in 2021 and then tumbled by 312541.0% in 2022.
  • Annual analysis of 5 years shows OptimizeRx's Income from Continuing Operations stood at -$2.2 million in 2020, then surged by 117.13% to $378079.0 in 2021, then plummeted by 3125.41% to -$11.4 million in 2022, then plummeted by 53.57% to -$17.6 million in 2023, then rose by 12.82% to -$15.3 million in 2024.
  • Its last three reported values are -$15.3 million in FY2024, -$17.6 million for FY2023, and -$11.4 million during FY2022.